These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12951808)

  • 1. Inhibitors of the entry of HIV into host cells.
    Meanwell NA; Kadow JF
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):451-61. PubMed ID: 12951808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped.
    Doms RW
    Top HIV Med; 2004; 12(4):100-3. PubMed ID: 15516706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
    J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
    Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
    Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of HIV-1 entry inhibitors as novel therapeutics.
    Pierson TC; Doms RW; Pöhlmann S
    Rev Med Virol; 2004; 14(4):255-70. PubMed ID: 15248253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
    Blanco J; Barretina J; Clotet B; Esté JA
    J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in targeting HIV-1 entry.
    Ryser HJ; Flückiger R
    Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral properties of two trimeric recombinant gp41 proteins.
    Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
    Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Coreceptors of HIV infection and the development of HIV entry inhibitors: overview and targets].
    Hoshino H
    Nihon Rinsho; 2002 Jan; 60(1):81-7. PubMed ID: 11808343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.
    Ueda H; Howard OM; Grimm MC; Su SB; Gong W; Evans G; Ruscetti FW; Oppenheim JJ; Wang JM
    J Clin Invest; 1998 Aug; 102(4):804-12. PubMed ID: 9710449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific CD4 down-modulating compounds with potent anti-HIV activity.
    Vermeire K; Schols D
    J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
    Veazey RS; Klasse PJ; Schader SM; Hu Q; Ketas TJ; Lu M; Marx PA; Dufour J; Colonno RJ; Shattock RJ; Springer MS; Moore JP
    Nature; 2005 Nov; 438(7064):99-102. PubMed ID: 16258536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
    Imai M; Baranyi L; Okada N; Okada H
    Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
    De Clercq E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.